Anthrax vaccine oral - AVANT Immunotherapeutics

Drug Profile

Anthrax vaccine oral - AVANT Immunotherapeutics

Alternative Names: Oral anthrax vaccine - AVANT Immunotherapeutics

Latest Information Update: 20 Jun 2007

Price : $50

At a glance

  • Originator AVANT Immunotherapeutics
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 03 May 2007 Discontinued - Preclinical for Anthrax in USA (PO)
  • 24 Feb 2004 This vaccine is still in active development
  • 29 Jul 2002 Preclinical trials in Anthrax in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top